Trials / Completed
CompletedNCT05905614
Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
An Open-label, Dose-escalation, Phase I Clinical Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPH4336 Tablets | Open-label SPH4336 Tablets ：Administered by oral |
Timeline
- Start date
- 2020-11-03
- Primary completion
- 2023-10-26
- Completion
- 2023-10-26
- First posted
- 2023-06-15
- Last updated
- 2024-06-17
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05905614. Inclusion in this directory is not an endorsement.